Abionyx Pharma SA - Asset Resilience Ratio
Abionyx Pharma SA (ABNX) has an Asset Resilience Ratio of 26.08% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Abionyx Pharma SA's Asset Resilience Ratio has changed over time. Check ABNX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Abionyx Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABNX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.87 Million | 26.08% |
| Total Liquid Assets | €3.87 Million | 26.08% |
Asset Resilience Insights
- Very High Liquidity: Abionyx Pharma SA maintains exceptional liquid asset reserves at 26.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abionyx Pharma SA Industry Peers by Asset Resilience Ratio
Compare Abionyx Pharma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Jinyu Bio-Technology Co Ltd
SHG:600201 |
Biotechnology | 1.20% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Abionyx Pharma SA (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Abionyx Pharma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.34% | €50.00K ≈ $58.46K |
€14.83 Million ≈ $17.34 Million |
+0.60pp |
| 2022-12-31 | -0.26% | €-41.00K ≈ $-47.93K |
€15.82 Million ≈ $18.50 Million |
-0.12pp |
| 2021-12-31 | -0.14% | €-31.00K ≈ $-36.24K |
€21.83 Million ≈ $25.52 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€10.29 Million ≈ $12.03 Million |
-- |
| 2019-12-31 | 73.85% | €7.57 Million ≈ $8.85 Million |
€10.25 Million ≈ $11.98 Million |
+1.56pp |
| 2018-12-31 | 72.30% | €9.50 Million ≈ $11.10 Million |
€13.13 Million ≈ $15.36 Million |
+7.90pp |
| 2016-12-31 | 64.39% | €18.72 Million ≈ $21.88 Million |
€29.07 Million ≈ $33.98 Million |
-- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more